Showing 1961-1970 of 3314 results for "".
- Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 Granted Orphan Drug Designation by EMAhttps://modernod.com/news/neurophth-therapeutics-treatment-of-lebers-hereditary-optic-neuropathy-gene-therapy-nr082-granted-orphan-drug-designation-by-ema/2480605/Neurophth Therapeutics announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) granted the orphan drug designation (ODD) for the company's leading gene therapy drug candidate, NR082 (rAAV2-ND4), for the treatment of Leber's hereditary opt
- Hubble Lenses Fined Millions After Settling Charges it Violated the Contact Lens Rule and FTC Act to Boost Saleshttps://modernod.com/news/hubble-lenses-fined-millions-after-settling-charges-it-violated-the-contact-lens-rule-and-ftc-act-to-boost-sales/2480604/New York City-based Vision Path, the online seller of direct-to-consumer Hubble lenses, will pay penalties and redress totaling $3.5 million to settle Federal Trade Commission (FTC) charges that it violated the Contact Lens Rule in several ways, including by failing to obtain prescriptions and to
- New Paper Examines Top 10 Myths About Fitting Soft Contact Lenseshttps://modernod.com/news/new-paper-examines-top-10-myths-about-fitting-soft-contact-lenses/2480598/A new peer-review paper from the Centre for Ocular Research & Education (CORE) seeks to shift persistent views about contact lenses that are no longer accurate based on current evidence. Addressing common myths and mis
- Mitotech to Host Key Opinion Leader Webinar on Visomitin: A Potential Treatment for Dry Eye Diseasehttps://modernod.com/news/mitotech-to-host-key-opinion-leader-webinar-on-visomitin-a-potential-treatment-for-dry-eye-disease/2480596/Mitotech announced that it will host a key opinion leader (KOL) webinar on Visomitin and its potential for the treatment of dry eye disease, on Friday, February 4, 2022 at 8 am EST (14.00 CET). The event will feature presentations from John D. Sheppard, MD, MMSc (Virginia Eye Consu
- Using Cryo-Electron Tomography, UCI Researchers Reveal Molecular Mechanisms Underlying Mutations Within the Eye that Lead to Blindnesshttps://modernod.com/news/uc-irvine-researchers-reveal-molecular-mechanisms-of-eye-disease-using-cryo-electron-tomography/2480586/For the first time, University of California, Irvine researchers in collaboration with the Max-Planck Institute of Biochemistry, have revealed, at a molecular level, key structural determinants of the highly specialized rod outer segment (ROS) membrane architecture of the eye, which is instrument
- Using Cryo-Electron Tomography, UCI Researchers Reveal Molecular Mechanisms Underlying Mutations Within the Eye that Lead to Blindnesshttps://modernod.com/news/using-cryo-electron-tomography-uci-researchers-reveal-molecular-mechanisms-underlying-mutations-within-the-eye-that-lead-to-blindness/2480552/For the first time, University of California, Irvine researchers in collaboration with the Max-Planck Institute of Biochemistry, have revealed at a molecular level key structural determinants of the highly specialized rod outer segment (ROS) membrane architecture of the eye, which is instrum
- Nicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and Nonclinical Developmenthttps://modernod.com/news/nicox-appoints-doug-hubatsch-as-new-chief-scientific-officer-to-lead-clinical-and-nonclinical-development/2480509/Nicox SA announced the appointment of Doug Hubatsch to lead all of the company’s nonclinical and clinical development activities. As Chief Scientific Officer, Mr. Hubatsch will be responsible for setting the research and development st
- AcuFocus Receives Approvable Letter From FDA for IC-8 Small Aperture IOLhttps://modernod.com/news/acufocus-receives-approvable-letter-from-fda-for-ic-8-small-aperture-iol/2480498/AcuFocus announced receipt of an Approvable Letter from the FDA for its IC-8
- Oyster Point Pharma Expands Executive Leadership Team to Support Commercialization of Tyrvaya Nasal Sprayhttps://modernod.com/news/oyster-point-pharma-announces-expansion-of-executive-leadership-team-to-support-commercialization-of-tyrvaya-nasal-spray/2480475/Oyster Point Pharma announced the promotion of Barry Rosenfeld, JD, as General Counsel; and Raegan A. McClain, JD, LLM, CCEP, as Chief Compliance Officer, both of whom will join the executive leadership team. “We are thrilled to expand our executive
- Euclid Systems Names Key Leadership Hires and Announces Major Facility Expansionhttps://modernod.com/news/euclid-systems-names-key-leadership-hires-and-announces-major-facility-expansion/2480465/Euclid Systems announced two additions to its leadership team as well as the expansion of its manufacturing facility in Sterling, Virginia. The changes come at a time when Euclid’s next-gene